



ANNOUNCEMENT

November 25, 2021

Portland Holdings appoints an International Business Development, Manager



BURLINGTON, ONTARIO –Portland Holdings group of companies (“Portland”), a Canadian privately held investment firm, is pleased to announce the appointment of Dr. Randy Peterson as the International Business Development Manager, Biotechnology. Dr. Peterson brings a wealth of experience within the pharmaceutical, biotech, and academic sectors. He will be focused on the commercialization of life science innovations, with a proficiency in the area of regulatory environments for new therapeutics, company creation and intellectual property protection.

“It is incredibly exciting to have Dr. Peterson join our organization and contribute through his commercial and scientific relationships to support Portland’s investments in strategies across multiple disciplines in biotechnology and life sciences,” said Michael Lee-Chin, Chairman of Portland.

“I am thrilled to join Portland and the life science team, providing insight and strategic guidance towards investments in innovative life science initiatives,” said Dr. Peterson. *“Almost daily, new discoveries in therapeutics hold the promise of revolutionizing healthcare. The rise of disruptive technologies have the potential to save lives and reduce the costs that could otherwise overburden healthcare systems. A key to unlocking the value of companies involved in therapeutics is a keen understanding of the underlying scientific principles, making Portland better equipped to identify and execute on investment opportunities,”* added Dr. Peterson.

Dr. Peterson graduated with an Honours Bachelor of Science in Biology from the University of Waterloo, obtained his Master’s degree in Molecular Genetics from the Faculty of Science, Department of Life Sciences, and Ph.D in Neuroscience from the Faculty of Health Sciences, Department of Medicine, at McMaster University. Dr. Peterson is currently working towards an MBA from the Goodman School of Business.

“Portland’s scientific leadership team has developed valuable strategic relationships, proficiency and technical skills within the life science industry. Through investments in biotech companies that are discovering and developing transformational new therapies, we aim to provide investors with access to quality investment opportunities which will ultimately result in an improved quality of life for patients,” added Michael Lee-Chin.

ABOUT THE PORTLAND GROUP

With investor roots dating back to 1987, Portland Holdings is a privately held investment company headquartered in Canada, that manages public equity, private equity and has a direct ownership interest in a collection of diversified businesses operating across multiple sectors including financial services, insurance, media, tourism, agriculture, real estate development, targeted radionuclide therapy, and more.

www.portlandholdings.com

CONTACT INFORMATION

Diana Oddi, Director, Communications and Marketing

T: (905) 331-4242

info@portlandholdings.com

Portland is not a financial services advisor and does not provide any professional investment opinions. Portland offers no warranty as to the advisability of the investment and it has no liability relating to the results of it.

Information presented in this material should be considered for background information only and should not be construed as investment or financial advice. Every effort has been made to ensure the utmost accuracy of the information provided. Information provided is believed to be reliable when posted. All information is subject to change from time to time without notice. Consent is required for any reproduction, in whole or in part, of this piece and/or of its images and concepts. PORTLAND HOLDINGS and the Shield Design are trademarks of Portland Holdings Limited.

*Portland Holdings, 1375 Kerns Road, Suite 100, Burlington, Ontario L7P 4V7 Tel.:1-888-331-4292 •
www.portlandholdings.com • info@portlandholdings.com*